Effect size (ES) of intervention on functional outcome in knee osteoarthritis
| Intervention | No of patients | Withdrawals | Control | Study length (days) | Functional outcome | ES | Blinding | Randomisati on | QS |
|---|---|---|---|---|---|---|---|---|---|
| Aceclofenac | 335 | 99 | Diclofenac | 182 | Lequesne | 0.04 | Double | Yes | 26 |
| Chondroitin sulphate | 146 | 20 | Diclofenac | 180 | Lequesne | 0.88 | Double | Yes | 20 |
| Chondroitin sulphate | 85 | 5 | Placebo | 182 | Lequesne | 1.01 | Double | Yes | 24 |
| Chondroitin sulphate | 127 | 6 | Placebo | 91 | Lequesne | 1.32 | Double | Yes | 21 |
| Diclofenac | 155 | 13 | Placebo | 15 | Lequesne | 0.62 | Double | Yes | 22 |
| GAGPS5-150 †(Arteparon) | 80 | 9 | Placebo | 182 | Lequesne | 0.11 | Double | Yes | 21 |
| Hyaluronic acid | 110 | 22 | Placebo | 343 (28) | Lequesne | 0.48 (0.42) | None | Yes | 22 |
↵5-150 Currently unavailable in Europe.
GAGPS = glycosaminoglycan polysulphuric acid